Kiniksa Pharmaceuticals International, plc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $0 $0 $0 $0 $0 $38.5m $220.2m $270.3m $423.2m $677.6m
Cost of Revenue $9.1m $47.0m $89.9m $60.9m $77.7m
Cost of goods sold $9.1m $47.0m $89.9m $60.9m $77.7m
Gross Profit (Calculated) (derived) $29.4m $173.2m $180.3m $362.3m $599.9m
Research and development $56.4m $86.6m $135.0m $112.0m $99.3m $65.5m $76.1m $111.6m $96.9m
Selling, general and administrative $29k $9.0m $21.6m $35.0m $45.3m $85.9m $98.0m $129.4m $168.0m $196.3m
Operating Expenses $348k $65.4m $108.2m $170.0m $157.4m $195.2m $210.4m $295.5m $468.9m $600.3m
Total operating expenses $348k $65.4m $108.2m $170.0m $157.4m $195.2m $210.4m $295.5m $468.9m $600.3m
Operating Income (Loss) ($833k) ($65.4m) ($108.2m) ($170.0m) ($157.4m) ($156.6m) $9.8m ($25.2m) ($45.6m) $77.2m
Additional Financial Items
Income (Loss) from Continuing Operations before Income Taxes, Domestic ($65.4m) ($105.6m) ($168.1m) ($162.0m) ($164.3m) ($84.1m) ($91.1m) ($7.7m) $2.8m
Income (loss) from operations ($833k) ($65.4m) ($108.2m) ($170.0m) ($157.4m) ($156.6m) $9.8m ($25.2m) ($45.6m) $77.2m
Other income, net $1.1m $97k $1.3m $8.5m $9.5m $11.6m
Income (loss) before income taxes ($64.9m) ($103.4m) ($163.9m) ($156.2m) ($156.5m) $11.0m ($16.7m) ($36.2m) $88.9m
Benefit (provision) for income taxes ($2k) $214k $2.0m ($5.2m) ($1.4m) $172.3m $30.7m ($7.0m) ($29.9m)
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax ($4k) $37k ($67k) ($32k) $110k ($38k) ($169k) $138k
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($64.9m) ($103.4m) ($163.9m) ($156.2m) ($156.5m) $11.0m ($16.7m) ($36.2m) $88.9m
Total other comprehensive income (loss) ($4k) $37k ($67k) ($32k) $110k ($38k) ($169k) $138k
Total comprehensive income (loss) ($1.5m) ($64.9m) ($103.2m) ($161.8m) ($161.4m) ($158.0m) $183.5m $14.0m ($43.4m) $59.1m
Net Income (Loss) Attributable to Parent ($1.5m) ($64.9m) ($103.2m) ($161.9m) ($161.4m) ($157.9m) $183.4m $14.1m ($43.2m) $59.0m
Earnings Per Share, Basic ($2.99) ($2.61) ($2.30) $2.64 $0.20 ($0.60) $0.80
Earnings Per Share, Diluted ($0.01) ($35.85) ($3.49) ($2.99) ($2.61) ($2.30) $2.60 $0.20 ($0.60) $0.75
Weighted Average Number of Shares Outstanding, Basic 54.0m 61.8m 68.6m 69.4m 70.1m 71.4m 74.2m
Weighted average ordinary shares outstanding, basic 54.0m 61.8m 68.6m 69.4m 70.1m 71.4m 74.2m
Weighted average ordinary shares outstanding, diluted 54.0m 61.8m 68.6m 70.4m 71.9m 71.4m 79.0m
Weighted Average Number of Shares Outstanding, Diluted 54.0m 61.8m 68.6m 70.4m 71.9m 71.4m 79.0m
Research and Development Expense $56.4m $86.6m $135.0m $112.0m $99.3m $65.5m $76.1m $111.6m $96.9m
General and Administrative Expense $29k $9.0m $21.6m $35.0m $45.3m $85.9m $98.0m $129.4m $168.0m $196.3m
Selling, General and Administrative Expense $13k $85.9m $98.0m $129.4m $168.0m $196.3m
Collaboration expenses $835k $24.1m $56.5m $128.3m $229.5m
Current Income Tax Expense (Benefit) $199k $764k $1.1m $791k $1.4m $13.2m $3.1m ($1.1m) $16.9m
Income Tax Expense (Benefit) $2k ($214k) ($2.0m) $5.2m $1.4m ($172.3m) ($30.7m) $7.0m $29.9m